Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Fbxo2 mediates clearance of damaged lysosomes and modifies neurodegeneration in the Niemann-Pick C brain
Elaine A. Liu, Mark L. Schultz, Chisaki Mochida, Chan Chung, Henry L. Paulson, Andrew P. Lieberman
Elaine A. Liu, Mark L. Schultz, Chisaki Mochida, Chan Chung, Henry L. Paulson, Andrew P. Lieberman
View: Text | PDF
Research Article Neuroscience

Fbxo2 mediates clearance of damaged lysosomes and modifies neurodegeneration in the Niemann-Pick C brain

  • Text
  • PDF
Abstract

A critical response to lysosomal membrane permeabilization (LMP) is the clearance of damaged lysosomes through a selective form of macroautophagy known as lysophagy. Although regulators of this process are emerging, whether organ- and cell-specific components contribute to the control of lysophagy remains incompletely understood. Here, we examined LMP and lysophagy in Niemann-Pick type C (NPC) disease, an autosomal recessive disorder characterized by the accumulation of unesterified cholesterol within late endosomes and lysosomes, leading to neurodegeneration and early death. We demonstrated that NPC human fibroblasts show enhanced sensitivity to lysosomal damage as a consequence of lipid storage. Moreover, we described a role for the glycan-binding F-box protein 2 (Fbxo2) in CNS lysophagy. Fbxo2 functions as a component of the S phase kinase-associated protein 1–cullin 1–F-box protein (SKP1-CUL1-SCF) ubiquitin ligase complex. Loss of Fbxo2 in mouse primary cortical cultures delayed clearance of damaged lysosomes and decreased viability after lysosomal damage. Moreover, Fbxo2 deficiency in a mouse model of NPC exacerbated deficits in motor function, enhanced neurodegeneration, and reduced survival. Collectively, our data identified a role for Fbxo2 in CNS lysophagy and establish its functional importance in NPC.

Authors

Elaine A. Liu, Mark L. Schultz, Chisaki Mochida, Chan Chung, Henry L. Paulson, Andrew P. Lieberman

×

Figure 8

Loss of Fbxo2 exacerbates the NPC disease phenotype.

Options: View larger image (or click on image) Download as PowerPoint
Loss of Fbxo2 exacerbates the NPC disease phenotype.
(A) Age-dependent p...
(A) Age-dependent performance on balance beam. Mice were trained at 5 weeks and run every other week starting at 6 weeks. The average of 3 trials was taken and max time was set at 20 seconds. N = 5 males and 5 females per genotype. (B) Performance on accelerating rotarod from 4–40 rpm at 9 weeks. N = 5 males and 5 females per genotype. (C) Kaplan-Meier survival curves. N = 6–10 males and 6–10 females per genotype. (D) Relative expression of Fbxo2, Fbxo6, and Fbxo27 was determined by qPCR in 8 weeks brainstem. N = 4 mice per genotype. (E) Quantification of Purkinje cell density in lobules IV and V of midline cerebellar sections. N = 3–4 mice per genotype. (F) The relative abundance of p62 in brainstem from 8 weeks mice was determined by Western blot. N = 5 mice per genotype. Data are shown as mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 by (A) 2-way ANOVA, (B, E, and F) 1-way ANOVA or (C) log-rank (Mantal-Cox) test and Gehan-Breslow-Wilcoxon test with (A and E) Bonferroni’s or (B and F) Tukey’s multiple comparisons [(A) F = 26.88, (B) F = 63.59, (E) F = 19.49, (F) F = 11.64]. Scale bar: 25 μm. Fbxo2, F-box protein 2; NPC, Niemann-Pick disease type C.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts